Neuroblastoma Biology Study

N2004-05: Neuroblastoma Biology Study

Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that may be related to the growth of neuroblastoma cells. Doctors and other medical scientists also want to find better ways to detect and measure neuroblastoma to improve the ability to follow the response of tumor cells to therapy.

Study Overview

• Status: Recruiting
• Conditions: Neuroblastoma

Detailed Description

The purposes of this study are:

To establish a storage place or bank of samples of blood, bone marrow, and/or tumor, and molecular components isolated from these samples from children with neuroblastoma. The stored specimens will be shared with laboratory researchers studying high risk neuroblastoma.

To collect clinical data (such as treatments received, date of diagnosis, tumor stage, etc) and radiology scans to provide this information as needed for the laboratory studies to be done on the specimens.

To obtain neuroblastoma tumor cells from tumor tissue, bone marrow, and/or blood to use to start cell lines, or tumor cells that will keep growing in the laboratory. These cell lines will be shared with laboratory researchers studying high risk neuroblastoma.

• Study Type: Observational
• Enrollment (Estimated): 1000

Contacts and Locations

• Study Contact: Name: Araz Marachelian, MD; Phone Number: 323-361-5687; Email: amarachelian@chla.usc.edu

Study Locations

• Canada
  • Ontario
    • Toronto, Ontario, Canada, M5G 1X8
      • Recruiting
      • Hospital for Sick Children
      • Contact: Daniel Morgenstern, MD
• United States
  • California
    • Los Angeles, California, United States, 90027-0700
      • Recruiting
      • Children's Hospital Los Angeles
      • Contact: Araz Marachelian, MD
    • Palo Alto, California, United States, 94305
      • Completed
      • Lucille Salter Packer Children's Hospital, Stanford University
    • San Francisco, California, United States, 94115
      • Recruiting
      • UCSF Helen Diller Family Comprehensive Cancer Center
      • Contact: Kieuhoa Vo, MD
  • Colorado
    • Aurora, Colorado, United States, 80045
      • Recruiting
      • Children Hospital of Colorado
      • Contact: Margaret Macy, MD
  • Georgia
    • Atlanta, Georgia, United States, 30322
      • Recruiting
      • AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus
      • Contact: Kelly Goldsmith, MD
  • Illinois
    • Chicago, Illinois, United States, 60637
      • Recruiting
      • University of Chicago, Comer Children's Hospital
      • Contact: Ami Desai, MD
  • Massachusetts
    • Boston, Massachusetts, United States, 02115
      • Recruiting
      • Children's Hospital Boston
      • Contact: Suzanne Shusterman, MD
  • Michigan
    • Ann Arbor, Michigan, United States, 48109
      • Recruiting
      • C.S Mott Children's Hospital
      • Contact: Rajen Mody, MD
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27599
      • Completed
      • University of North Carolina
  • Ohio
    • Cincinnati, Ohio, United States, 45229-3039
      • Recruiting
      • Cincinnati Children's Hospital Medical Center
      • Contact: Katherine Somers, MD
    • Columbus, Ohio, United States, 43205
      • Recruiting
      • Nationwide Children's Hospital
      • Contact: Keri Streby, MD
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19104-4318
      • Recruiting
      • Children's Hospital of Philadelphia
      • Contact: Yael Mosse, MD
  • Tennessee
    • Memphis, Tennessee, United States, 38105
      • Not yet recruiting
      • St. Jude Children's Research Hospital
      • Contact: Sara Federico, MD
  • Texas
    • Dallas, Texas, United States, 75235
      • Not yet recruiting
      • University of Texas Southwestern
      • Contact: Tanya Watt, MD
    • Fort Worth, Texas, United States, 76104
      • Recruiting
      • Cook Children's Medical Center - Fort Worth
      • Contact: Chelsee Greer, DO
  • Washington
    • Seattle, Washington, United States, 98105
      • Recruiting
      • Seattle Children's Hospital
      • Contact: Mark Fluchel, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 month to 99 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Neuroblastoma patients from various NANT sites.

Description

Inclusion Criteria:

• Patients must be greater than or 31 days of age.
• Patients must have had a diagnosis of high risk neuroblastoma either by histological verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines.
• All patients with refractory or recurrent high risk neuroblastoma at NANT institutions are eligible regardless of disease status (including no measurable or evaluable tumor) as long as they undergo a disease evaluation and appropriate samples are submitted.
• Additionally, all patients with high risk neuroblastoma without relapse treated at a NANT institution are eligible if undergoing a disease evaluation, as long as Children's Oncology Group specimens are prioritized.

Exclusion Criteria:

• There are no exclusion criteria on this study.

Study Plan

How is the study designed?

Collaborators and Investigators

• Sponsor: New Approaches to Neuroblastoma Therapy Consortium
• Investigators: Study Chair: Shahab Asgharzadeh, MD, Children's Hospital Los Angeles

Study record dates

Study Major Dates

• Study Start: July 1, 2011
• Primary Completion (Estimated): December 1, 2099
• Study Completion (Estimated): December 1, 2099

Study Registration Dates

• First Submitted: April 26, 2012
• First Submitted That Met QC Criteria: April 27, 2012
• First Posted (Estimated): April 30, 2012

Study Record Updates

• Last Update Posted (Actual): March 23, 2026
• Last Update Submitted That Met QC Criteria: March 19, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Neuroectodermal Tumors, Primitive, Peripheral; Neuroectodermal Tumors, Primitive; Neuroblastoma
• Other Study ID Numbers: N2004-05